In order to develop novel chemotherapeutic agents with potent anticancer activities, a series of new 2,5-diaryl/heteroaryl-1,3,4-oxadiazoles were designed and synthesized. The structures of the new compounds were established using elemental analyses, IR and NMR spectral data. The compounds were evaluated for their anticancer potential on two standardized human cell lines, HT-29 (colon adenocarcinoma) and MDA-MB-231 (breast adenocarcinoma). Cytotoxicity was measured by MTS assay, while cell cycle arrest and apoptosis assays were conducted using a flow cytometer, the results showing that the cell line MDA-MB-231 is more sensitive to the compounds’ action. The results of the predictive studies using the PASS application and the structural similarity analysis indicated STAT3 and miR-21 as the most probable pharmacological targets for the new compounds. The promising effect of compound 3e, 2-[2-(phenylsulfanylmethyl)phenyl]-5-(4-pyridyl)-1,3,4-oxadiazole, especially on the MDA-MB-231 cell line motivates future studies to improve the anticancer profile and to reduce the toxicological risks. It is worth noting that 3e produced a low toxic effect in the D. magna 24 h assay and the predictive studies on rat acute toxicity suggest a low degree of toxic risks.
为了开发具有强大抗癌活性的新型化疗药物,设计并合成了一系列新的2,5-二芳基/杂芳基-1,3,4-噁二唑化合物。通过元素分析、红外光谱和核磁共振光谱数据,确认了新化合物的结构。对这些化合物在两种标准化的人类细胞系HT-29(结肠腺癌)和MDA-MB-231(乳腺腺癌)上的抗癌潜力进行了评估。通过MTS测定细胞毒性,利用流式细胞仪进行细胞周期阻滞和凋亡实验,结果表明MDA-MB-231细胞系对这些化合物的作用更为敏感。利用PASS应用程序和结构相似性分析进行的预测研究结果显示,STAT3和miR-21是新化合物最可能的药理靶点。化合物3e,2-[2-(苯基硫基甲基)苯基]-5-(4-吡啶基)-1,3,4-噁二唑,特别对MDA-MB-231细胞系的显著效果,激发了未来改善抗癌特性和减少毒理风险的研究动力。值得注意的是,3e在D. magna 24小时实验中产生了低毒效应,并且对大鼠急性毒性的预测研究表明毒性风险程度较低。